# BPC-157 TB-500 References: The Cited Source Record

> BPC-157 TB-500 references: the full citation register behind this reference, including the BPC-157 tendon and VEGFR2 studies, the Thymosin Beta-4 literature, and the FDA 503A source pages.

Every quantitative claim on this site resolves to an entry below. Peer-reviewed studies carry a DOI or PubMed link; regulatory facts carry the FDA source page.

## How to Read These References

These BPC-157 TB-500 references are the source record for the reference. The peer-reviewed entries divide cleanly along the two constituent channels: the BPC-157 leg (the transected-tendon finding, the VEGFR2-Akt-eNOS angiogenesis study, the Src-Caveolin-1-eNOS vasomotor work) and the TB-500 / Thymosin Beta-4 leg (the actin-sequestration crystal structure, the multi-functional review, the angiogenesis and wound-healing demonstration, the doping-control synthesis of the `Ac-LKKTETQ` fragment).

The newer entries are the bounding reviews — the 2025 BPC-157 systematic review (`PMID 40756949`), the 2026 musculoskeletal-peptide narrative review, and the 2025 "Regeneration or Risk?" narrative review — which are why this reference states the combination has no controlled clinical evidence. The final entries are the FDA pages underpinning the 503A Category 2 status and the access framework. Numbered citations `[1]` through `[18]` throughout the site resolve here.

## References

[1] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. (BPC-157 chemical identity and PK reference points cited throughout.) https://pubmed.ncbi.nlm.nih.gov/14554208/
[2] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[3] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. https://pubmed.ncbi.nlm.nih.gov/15329672/
[4] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
[5] Staresinic M, et al. Effects of pentadecapeptide BPC 157 on the rabbit/rat transected Achilles tendon model (transected-tendon healing and tendocyte outgrowth). J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[6] Philp D, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004. https://pubmed.ncbi.nlm.nih.gov/15037013/
[7] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. https://pubmed.ncbi.nlm.nih.gov/22962027/
[8] Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10:17078. https://pubmed.ncbi.nlm.nih.gov/33051481/
[11] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. (36 studies, 35 preclinical, 1 human; "no clinical safety data"; no mention of TB-500 or any combination/blend.) https://pubmed.ncbi.nlm.nih.gov/40756949/
[12] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. (Lists both BPC-157 and TB-500/thymosin beta-4; rigorous human safety data scarce; potential for serious harm; largely outside regulatory oversight.) https://pubmed.ncbi.nlm.nih.gov/41966639/
[13] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. (Human data limited to three pilot studies; should be considered investigational.) https://pubmed.ncbi.nlm.nih.gov/40789979/
[14] Human single-agent pharmacokinetic and safety reference points for full-length Thymosin Beta-4 (NOT the TB-500 heptapeptide): intravenous Tbeta4 well tolerated to 1260 mg with dose-proportional PK (Ruff et al., Phase 1, 40 volunteers) and to 25 microg/kg single / 5 microg/kg-daily x 10 days (first-in-human study, 2021), as summarized in the dosage-research context of the compound corpus. See also ref [4] for the consolidated Thymosin Beta-4 clinical-development review. https://pubmed.ncbi.nlm.nih.gov/22074294/
[15] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (BPC-157 (free base) / BPC-157 acetate placed in Category 2 for 503A compounding; list entry effective September 29, 2023; page verified loading and containing the BPC-157 entry on 2026-05-29.) https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[16] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. ("Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" placed in Category 2 for 503A compounding; list entry effective September 29, 2023; page verified loading and containing the entry on 2026-05-29.) https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[17] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the 503A/503B framework; bulk-substance eligibility rules; PCAC role; FDA approval of a finished drug is separate from compounding eligibility. Verified 2026-05-29.) https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[18] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Public calendar listing BPC-157 and TB-500 among substances "being considered for inclusion on the 503A Bulks List"; a scheduled discussion under evaluation, NOT a decision or outcome. Verified 2026-05-29.) https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

---

A documentation-style reference on the BPC-157 TB-500 blend — each constituent's findings logged to its own studies, the combination left as an empty entry because no controlled trial exists, and the FDA 503A Category 2 status read from the source; no clinic compiled it and nothing here is dispensed or sold.